Skip to main content
Oncoinvent ASA logo

Oncoinvent ASA — Investor Relations & Filings

Ticker · OCIN ISIN · NO0010779341 LEI · 54930076H5GUZRMSNR39 Euronext Growth Manufacturing
Open in API
Filings indexed 138 across all filing types
Latest filing 2026-02-17 Regulatory Filings
Country NO Norway
Listing Euronext Growth OCIN

About Oncoinvent ASA

https://www.oncoinvent.com/

Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies for cancer. The company's core focus is on direct alpha therapy, a technology platform designed to deliver potent, short-range radiation directly to cancerous tumors. Its lead product candidate, Radspherin®, is composed of inorganic microparticles that carry the alpha-emitting radionuclide Radium-224. This formulation is engineered for regional retention and slow degradation, enabling a high radiation dose to be administered within the peritoneal cavity while minimizing systemic exposure. Oncoinvent's clinical programs are primarily investigating the use of Radspherin® for treating metastatic cancers in the peritoneal cavity, including ovarian and colorectal cancer.

Recent filings

Filing Released Lang Actions
Oncoinvent to Present Positive 24-month Follow-up Data from Phase 1 Ovarian Cancer Study of Radspherin[®] at ESGO 2026
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Oncoinvent will present clinical trial data (Phase 1 Ovarian Cancer Study) at an upcoming medical conference (ESGO 2026). It provides highlights of the study results but is not a formal financial report, audit, or regulatory filing. As it is a corporate announcement regarding clinical progress and upcoming presentations, it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2026-02-17 English
Financial calendar
Report Publication Announcement Classification · 95% confidence The document is a short, 478-character notice listing future dates for the publication of various financial reports and the Annual General Meeting. It does not contain the actual reports themselves, but rather serves as a schedule or announcement of upcoming reporting events. Under the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA).
2026-02-03 English
Finansiell kalender
Report Publication Announcement Classification · 95% confidence The document is a 'Finansiell kalender' (Financial Calendar) for Oncoinvent ASA, which lists the scheduled dates for the release of future annual reports, quarterly reports, and the annual general meeting. Since it is a short announcement regarding the timing and publication of future reports rather than the reports themselves, it falls under the category of a Report Publication Announcement.
2026-02-03 Norwegian
Four additional sites open for recruitment in Oncoinvent's Phase 2 trial
Regulatory Filings Classification · 95% confidence The document is a press release issued by Oncoinvent regarding the operational update of their Phase 2 clinical trial (opening of new sites and patient enrollment). It does not fit into financial reporting categories like 10-K, IR, or ER, nor does it represent a corporate governance or shareholder event. As it is a general regulatory/corporate announcement regarding business operations that does not fall into the other specific categories, it is classified as a Regulatory Filing (RNS).
2026-01-29 English
Oncoinvent ASA: Registration of reverse share split
Share Issue/Capital Change Classification · 100% confidence The document announces the registration of a reverse share split with the Norwegian Register of Business Enterprises. This directly relates to a change in the company's capital structure (share count and nominal value). According to the provided definitions, announcements regarding stock splits or capital changes fall under the 'Share Issue/Capital Change' (SHA) category.
2026-01-20 English
Oncoinvent ASA: Ex. reverse share split and change of ISIN today
Share Issue/Capital Change Classification · 100% confidence The document announces a corporate action regarding a reverse share split, including details on the split ratio, new par value, new ISIN, and the resulting number of shares outstanding. This falls directly under the category of capital changes or share structure adjustments, which is classified as 'SHA' (Share Issue/Capital Change).
2026-01-19 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.